BLSM Stock Forecast: Blossomhill Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 20 Nov 2026
$15
+0.69% on the day

The 5 Wall Street analysts covering Blossomhill Therapeutics, Inc. hold a median 12-month price target of $35 — +141.2% from the last close. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 1 of 100 as at 21 Nov 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$461.2M
Ticker Nerd rank
1/ 100
Median analyst target
$35
Analysts covering
5
Total return, dividends reinvested
1W
+3.5%
1M
+0.8%
From high
−45.9%
From low
+17.5%
$12
$27
Range since 7 Aug 2026, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores Blossomhill Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
1/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Revisions
25
Value
19
Growth
10
Accruals
5
Issuance
4
Momentum
3
Quality
2
Volatility
1

Revisions (25): Analysts have, on balance, been raising their forecasts.

Volatility (1): The share price moves around a lot.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

BLSM stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on BLSM, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, since 7 Aug 2026Adjusted close, US dollars
$10$15$20$25$30$35$40$45Sep 26Oct 26Nov 26BLSMHigh $40Median $35Low $30

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says5 analysts
5
Buy
0
Hold
0
Sell
$30
Low
$35
Median
$40
High

The green dot is the last close — the median target sits +141.2% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
21 Sept 2026GuggenheimMaintainsBuy$30 → $40
21 Sept 2026Leerink PartnersMaintainsOutperform$36 → $40
1 Sept 2026GuggenheimInitiatesBuy$30
1 Sept 2026HC Wainwright & Co.InitiatesBuy$35
1 Sept 2026JP MorganInitiatesOverweight$28
1 Sept 2026Leerink PartnersInitiatesOutperform—
1 Sept 2026LifeSci CapitalInitiatesOutperform—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for BLSM.

Market Radar

This page is one stock. Monday covers all of them.

BLSM appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

BLSM vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

BLSM vs S&P 500, last 12 monthsTotal return, rebased to 100
80100120140160180Sep 26Oct 26Nov 26BLSMS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

BLSM analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
0
Analysts cutting
0
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
—
Price / sales
—
Price / book
—
EV / EBITDA
—
Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
—
Net margin
—
Returns & dividend
Return on equity
—
Return on assets
−37.2%

Higher than 11% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Blossomhill Therapeutics, Inc. has a market value of $461.2M and an enterprise value of $256.5M.

  • Shares outstanding: 29.1M.

  • Blossomhill Therapeutics, Inc. employs 69 people.

market figures as at 22 Nov 2026

Data provided by Twelve Data

Peers

BLSM and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
BLSMBlossomhill Therapeutics, Inc.$461.2M1
DMACDiaMedica Therapeutics, Inc.$444.9M55
PRTAProthena Corp. Plc$442.5M90
STTKShattuck Labs, Inc.$447.6M61
ASMBAssembly Biosciences, Inc.$439.7M79
CTMXCytomX Therapeutics, Inc.$438.8M46
CAPRCapricor Therapeutics, Inc.$436.5M13

Take a look at BLSM’s peer groups, ranked by the model: healthcare stocks · biotech stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own Blossomhill Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about BLSM

What is the BLSM stock price forecast for 2026-2027?

The 5 Wall Street analysts covering Blossomhill Therapeutics, Inc. have a median 12-month price target of $35, with estimates ranging from $30 to $40. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is BLSM stock a buy right now?

Of the 5 analysts covering Blossomhill Therapeutics, Inc., 5 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Blossomhill Therapeutics, Inc. 1 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank BLSM?

As at 21 Nov 2026, Blossomhill Therapeutics, Inc. ranks 1 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Revisions (25 of 100).

Will BLSM stock go up?

No one can know that. What the data says: the median 12-month target from 5 analysts implies +141.2% from the last close, and Ticker Nerd's factor model ranks Blossomhill Therapeutics, Inc. 1 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the BLSM stock forecast for 2030?

No analyst covering Blossomhill Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for BLSM are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $30 to $40 over the next 12 months.

What does Blossomhill Therapeutics, Inc. do?

BlossomHill Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing small molecule medicines for cancer treatment. The company applies a chemistry-based approach to design investigational therapies aimed at addressing unmet medical needs in oncology.

Company

About Blossomhill Therapeutics, Inc.

BlossomHill Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing small molecule medicines for cancer treatment. The company applies a chemistry-based approach to design investigational therapies aimed at addressing unmet medical needs in oncology. Its current pipeline includes programs for EGFR-mutant non-small cell lung cancer, relapsed or refractory acute myeloid leukemia, and higher-risk myelodysplastic syndromes, reflecting a focus on difficult-to-treat blood and solid tumors. BlossomHill Therapeutics also advances preclinical candidates targeting pathways relevant to cancer biology, including KRAS-driven disease. Headquartered in San Diego, California, BlossomHill Therapeutics operates within the biotechnology sector and centers its work on drug discovery and clinical development.

CEO Dr. Jingrong Jean Cui Ph.D. · 69 employees · United States · https://bhtherapeutics.com